¿¬¼ö°­ÁÂ
´ëÇѺñ´¢±âÁ¾¾çÇÐȸ The 21st KUOS Multidisciplinary Conference(2ÀÏÂ÷) : 2023-03-25

´ëÇѺñ´¢±âÁ¾¾çÇÐȸ The 21st KUOS Multidisciplinary Conference(2ÀÏÂ÷) : 2023-03-25
±³À°ÀÏÀÚ : 2023-03-25
±³À°Àå¼Ò : ¼¼Á¾´ëÇб³ ±¤°³Åä°ü ÁöÇÏ2Ãþ ÄÁº¥¼Ç¼¾ÅÍ

±³À°ÁÖÁ¦ : The 21st KUOS Multidisciplinary Conference(2ÀÏÂ÷)

ÁÖÃÖ±â°ü : ´ëÇѺñ´¢±âÁ¾¾çÇÐȸ
´ã´çÀÚ : ±èÀºÁÖ
¿¬¶ôó : 02-704-8574  

À̸ÞÀÏ : app@app2010.com

±³À°Á¾·ù : ºñ´¢ÀÇÇаú

Âü¼®¿¹»óÀοø : 200¸í
Èñ¸ÁÆòÁ¡ : 5Á¡

Áö¿ª : ¼­¿ïƯº°½Ã
±³À°½Ã°£ : 5 ½Ã°£ 20ºÐ

¼¼ºÎ¼ö°­·á : 30,000¿ø  

ºñ°í Àü¹®ÀÇ: 30,000¿ø / Àü°øÀÇ, ±ºÀÇ°ü, °£È£»ç: 20,000¿ø


±¸ºÐ ¿ùÀÏ °­ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °­»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ

±âŸ 03-25 ¼¼Á¾´ëÇб³ ±¤°³Åä°ü ÁöÇÏ2Ãþ ÄÁº¥¼Ç¼¾ÅÍ 08:10~08:40 Registration ()

±âŸ 03-25 ¼¼Á¾´ëÇб³ ±¤°³Åä°ü ÁöÇÏ2Ãþ ÄÁº¥¼Ç¼¾ÅÍ 08:40~09:00 President¡¯s Welcome ()

±³À°½Ã°£ 03-25 ¼¼Á¾´ëÇб³ ±¤°³Åä°ü ÁöÇÏ2Ãþ ÄÁº¥¼Ç¼¾ÅÍ 09:00~09:20 Introducing PI-QUAL (Prostate Imaging Quality) Score Àå¿ø(ÀüºÏÀÇ´ë ¿µ»óÀÇÇаú)

±³À°½Ã°£ 03-25 ¼¼Á¾´ëÇб³ ±¤°³Åä°ü ÁöÇÏ2Ãþ ÄÁº¥¼Ç¼¾ÅÍ 09:20~09:40 AI (Artificial Intelligence) application ±èÂù±³(¼º±Õ°üÀÇ´ë ¿µ»óÀÇÇаú)

±³À°½Ã°£ 03-25 ¼¼Á¾´ëÇб³ ±¤°³Åä°ü ÁöÇÏ2Ãþ ÄÁº¥¼Ç¼¾ÅÍ 09:40~09:57 Role of metastatectomy in RCC: Where do we stand? ¹ÚÁø¼º(À»ÁöÀÇ´ë ºñ´¢ÀÇÇаú)

±³À°½Ã°£ 03-25 ¼¼Á¾´ëÇб³ ±¤°³Åä°ü ÁöÇÏ2Ãþ ÄÁº¥¼Ç¼¾ÅÍ 09:57~10:14 Which approach is better for 1st line treatment in mRCC ½Å»óÁØ(¿¬¼¼ÀÇ´ë Á¾¾ç³»°ú)

±³À°½Ã°£ 03-25 ¼¼Á¾´ëÇб³ ±¤°³Åä°ü ÁöÇÏ2Ãþ ÄÁº¥¼Ç¼¾ÅÍ 10:14~10:30 SBRT on renal cell carcinoma: an overview of technical aspects and biological rationale ÀÓÁÖÇÑ(ÀÎÇÏÀÇ´ë Á¾¾ç³»°ú)

ÈÞ½Ä 03-25 ¼¼Á¾´ëÇб³ ±¤°³Åä°ü ÁöÇÏ2Ãþ ÄÁº¥¼Ç¼¾ÅÍ 10:30~10:50 Break ()

±³À°½Ã°£ 03-25 ¼¼Á¾´ëÇб³ ±¤°³Åä°ü ÁöÇÏ2Ãþ ÄÁº¥¼Ç¼¾ÅÍ 10:50~11:20 Genomic Testing and treatment with PARP-inhibitors in Patients with MetastaticCastration-resistant Prostate Cancer: A Pragmatic Guide for Clinicians in view of the recent data Axel Merseburger MD PhD((University Hospital Schleswig-HolsteinLübeck Germany)

±³À°½Ã°£ 03-25 ¼¼Á¾´ëÇб³ ±¤°³Åä°ü ÁöÇÏ2Ãþ ÄÁº¥¼Ç¼¾ÅÍ 11:20~11:37 Role of the prostate- and/or metastasis-directed radiation for oligometastatic HSPC ±Ç¹Î¼±(¾ÆÁÖÀÇ´ë Á¾¾ç³»°ú)

±³À°½Ã°£ 03-25 ¼¼Á¾´ëÇб³ ±¤°³Åä°ü ÁöÇÏ2Ãþ ÄÁº¥¼Ç¼¾ÅÍ 11:37~11:54 Surgery for micro-metastatic HSPC diagnosed by PSMA PET/CT after definitive treatment ±è¼ºÈ¯(°¡Å縯ÀÇ´ë ¹æ»ç¼±Á¾¾çÇаú)

±³À°½Ã°£ 03-25 ¼¼Á¾´ëÇб³ ±¤°³Åä°ü ÁöÇÏ2Ãþ ÄÁº¥¼Ç¼¾ÅÍ 11:54~12:10 Update in the systemic management for low volume mHSPC ÀÌÈ¿Áø(Ãæ³²ÀÇ´ë Á¾¾ç³»°ú)

½Ä»ç 03-25 ¼¼Á¾´ëÇб³ ±¤°³Åä°ü ÁöÇÏ2Ãþ ÄÁº¥¼Ç¼¾ÅÍ 12:10~13:40 Lunch ()

±³À°½Ã°£ 03-25 ¼¼Á¾´ëÇб³ ±¤°³Åä°ü ÁöÇÏ2Ãþ ÄÁº¥¼Ç¼¾ÅÍ 13:40~14:00 Role of surgery in metastatic PPGL ±è¿Ï¼®(ÀÌÈ­ÀÇ´ë ºñ´¢ÀÇÇаú)

±³À°½Ã°£ 03-25 ¼¼Á¾´ëÇб³ ±¤°³Åä°ü ÁöÇÏ2Ãþ ÄÁº¥¼Ç¼¾ÅÍ 14:00~14:20 Newer diagnostic & therapeutic modalities in PPGL ±è¿¬ÁÖ(¿ï»êÀÇ´ë ¹æ»ç¼±Á¾¾çÇаú)

±³À°½Ã°£ 03-25 ¼¼Á¾´ëÇб³ ±¤°³Åä°ü ÁöÇÏ2Ãþ ÄÁº¥¼Ç¼¾ÅÍ 14:20~14:50 PSMA Targeted Radioligand Therapy: Current Status and Future Directions Phillip Koo MD FACS(Division Chief of Diagnostic Imaging at the Banner MD Anderson Cancer Center in Arizona)

ÈÞ½Ä 03-25 ¼¼Á¾´ëÇб³ ±¤°³Åä°ü ÁöÇÏ2Ãþ ÄÁº¥¼Ç¼¾ÅÍ 14:50~15:10 Break ()

±³À°½Ã°£ 03-25 ¼¼Á¾´ëÇб³ ±¤°³Åä°ü ÁöÇÏ2Ãþ ÄÁº¥¼Ç¼¾ÅÍ 15:10~15:30 Kidney ÀÌÁ¤Çö(°í·ÁÀÇ´ë º´¸®°ú)

±³À°½Ã°£ 03-25 ¼¼Á¾´ëÇб³ ±¤°³Åä°ü ÁöÇÏ2Ãþ ÄÁº¥¼Ç¼¾ÅÍ 15:30~15:50 Urinary bladder and prostate Ȳ¼öÇö(¼º±Õ°üÀÇ´ë º´¸®°ú)

±³À°½Ã°£ 03-25 ¼¼Á¾´ëÇб³ ±¤°³Åä°ü ÁöÇÏ2Ãþ ÄÁº¥¼Ç¼¾ÅÍ 15:50~16:10 Treatment of Huge Non-muscle invasive bladder cancer without high grade ±¸ÀÚÇö(¼­¿ïÀÇ´ë ºñ´¢ÀÇÇаú)

±³À°½Ã°£ 03-25 ¼¼Á¾´ëÇб³ ±¤°³Åä°ü ÁöÇÏ2Ãþ ÄÁº¥¼Ç¼¾ÅÍ 16:10~16:30 Radiation therapy for BCG-unresponsive NMIBC ±èÀÎÈ£(°¡Å縯ÀÇ´ë Á¾¾ç³»°ú)

±âŸ 03-25 ¼¼Á¾´ëÇб³ ±¤°³Åä°ü ÁöÇÏ2Ãþ ÄÁº¥¼Ç¼¾ÅÍ 16:30~16:40 Çмú»ó ½Ã»ó½Ä ()

±âŸ 03-25 ¼¼Á¾´ëÇб³ ±¤°³Åä°ü ÁöÇÏ2Ãþ ÄÁº¥¼Ç¼¾ÅÍ 16:40~17:10 Æóȸ ¹× ÃÑȸ ()

 

  • ÃßõÇϱâ
Tip. ±³À°ÀÏÁ¤Àº ±³À°±â°üÀÇ »çÁ¤¿¡ µû¶ó º¯°æµÉ ¼ö ÀÖÀ¸¹Ç·Î »çÀü¿¡ ¹Ýµå½Ã ±³À°±â°üÀ¸·Î ¹®ÀÇÇÏ¿© È®ÀÎ ¹Ù¶ø´Ï´Ù.
¡å
ÀÛ¼ºÀÚ   ºñ¹Ð¹øÈ£
 
¿¬¼ö°­Á ÁÖ°£º£½ºÆ®
Á¦¸ñ

[¼­¿ï] 2024 ½ÉÀå»öÀü¿¬±¸È¸ ½ÉÆ÷Áö¿ò : 2024-03-30

±³À°ÀÏÀÚ : 2024-03-30 ±³À°Àå¼Ò : »ï¼º¼­¿ïº´¿ø ÀÏ¿ø¿ª»ç Bµ¿ 9Ãþ È÷Æ÷Å©¶óÅ×½ºÈ¦ ±³À°ÁÖÁ¦ : 2024 ½ÉÀå»öÀü¿¬±¸È¸ ½ÉÆ÷Áö¿òÁÖÃÖ±â°ü : ´ëÇѳúÁ¹ÁßÇÐȸ ½ÃÇà±â°ü(ÁöºÎ/

Ãßõ¼ö : 0 , Á¶È¸¼ö : 7,085 , ´ñ±Û¼ö : 0

[¼­¿ï] (¿Â¶óÀÎ) 2024³â Á¦5ȸ ½Å¼ººóÇ÷¿¬±¸È¸ ¿¬¼ö°­Á : 2024-03-09

±³À°ÀÏÀÚ : 2024-03-09 ±³À°Àå¼Ò : (¿Â¶óÀÎ) ±³À°ÁÖÁ¦ : (¿Â¶óÀÎ) 2024³â Á¦5ȸ ½Å¼ººóÇ÷¿¬±¸È¸ ¿¬¼ö°­ÁÂÁÖÃÖ±â°ü : ´ëÇѽÅÀåÇÐȸ ½ÃÇà±â°ü(ÁöºÎ/°ú) : ½Å¼ººóÇ÷¿¬

Ãßõ¼ö : 0 , Á¶È¸¼ö : 7,055 , ´ñ±Û¼ö : 0

[¼­¿ï] Á¦26Â÷ °¡Å縯ÀÇ´ë ½ÅÀå³»°ú ¿¬¼ö±³À° (Clinical Topics on Hemodialysis Vascular Access) : 2024-03-31

±³À°ÀÏÀÚ : 2024-03-31 ±³À°Àå¼Ò : °¡Å縯ÀÇ´ë ¼ºÀÇȸ°ü ¸¶¸®¾ÆȦ ±³À°ÁÖÁ¦ : Á¦26Â÷ °¡Å縯ÀÇ´ë ½ÅÀå³»°ú ¿¬¼ö±³À° (Clinical Topics on Hemodialy

Ãßõ¼ö : 0 , Á¶È¸¼ö : 7,097 , ´ñ±Û¼ö : 0

[¼­¿ï] (¿Â¶óÀÎ)Á¦27Â÷ ´ç´¢º´ ±³À°ÀÚ ¿¬¼ö°­Á : 2024-03-30

±³À°ÀÏÀÚ : 2024-03-30 ±³À°Àå¼Ò : ¿Â¶óÀÎ »ýÁß°è ±³À°ÁÖÁ¦ : (¿Â¶óÀÎ)Á¦27Â÷ ´ç´¢º´ ±³À°ÀÚ ¿¬¼ö°­ÁÂÁÖÃÖ±â°ü : ´ëÇÑ´ç´¢º´ÇÐȸ ´ã´çÀÚ : °û¼ÖÀÌ ¿¬¶ôó : 02-71

Ãßõ¼ö : 0 , Á¶È¸¼ö : 7,184 , ´ñ±Û¼ö : 0

[¼­¿ï] ´ëÇÑÁ¶Çöº´ÇÐȸ Treatment and management of symptoms and physical health in schizophrenia : 2024-04-2..

±³À°ÀÏÀÚ : 2024-04-26 ±³À°Àå¼Ò : ¹é¹ü±è±¸±â³ä°ü ±³À°ÁÖÁ¦ : Treatment and management of symptoms and physical health i

Ãßõ¼ö : 0 , Á¶È¸¼ö : 6,786 , ´ñ±Û¼ö : 0